Innoviva
INVA
21.06
+0.23
+1.10%
Innoviva
US · INVA
#2990 by market cap
Listed 1970
21.06
+0.23
+1.10%
Live - 5344 symbols - heartbeat 401s ago
· 2026-10-08 07:40
Pre-market
20.91
-0.71%
After-hours
21.06
0.00%
Overnight
21.06
0.00%
- Market cap
- 1.52B
- P/E (TTM)i
- 4.89
- P/Bi
- 1.23
- EPSi
- 3.30
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on INVA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.28, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +14.67% YoY
Margins
- Gross margin
- 81.19%
- Operating margin
- 39.81%
- Net margin
- 65.92%
Key ratios & quality
- Enterprise valuei
- 1.21B
- PEG ratioi
- 0.59
- Altman Z-Scorei
- 3.28
PEG uses trailing P/E against the 3-year net income growth rate (8.22%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 261.00M | 261.02M | 336.79M | 391.87M | 331.34M | 310.46M | 358.71M | 411.33M |
| Gross profit | -- | -- | 336.79M | 391.87M | 317.55M | 267.82M | 322.11M | 333.94M |
| Selling & admin expenses | 22.75M | 14.66M | 13.88M | 16.19M | 63.54M | 98.23M | 115.69M | 113.32M |
| Research & development | 0 | 0 | 1.79M | 576.00K | 41.43M | 33.92M | 13.65M | 30.60M |
| Operating profit | 238.25M | 246.36M | 321.12M | 375.10M | 207.00M | 113.89M | 166.87M | 163.75M |
| Pretax profit | 210.26M | 232.90M | 354.25M | 445.28M | 286.95M | 194.10M | 37.39M | 326.86M |
| Tax | -196.07M | 41.90M | 60.43M | 76.44M | 66.69M | 14.38M | 14.00M | 55.70M |
| Net profit | 406.33M | 190.99M | 293.81M | 368.84M | 220.26M | 179.72M | 23.39M | 271.17M |
| Basic EPS | 4 | 2 | 2 | 3 | 3 | 3 | 0 | 4 |
| Diluted EPS | 3.53 | 1.43 | 2.02 | 2.87 | 2.37 | 2.20 | 0.36 | 3.30 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 88.63M | 100.28M | 107.80M | 114.61M | 97.99M | 119.59M |
| Gross profit | 79.79M | 83.15M | 75.54M | 101.94M | 82.39M | 90.62M |
| Selling & admin expenses | 27.49M | 26.41M | 27.29M | 32.12M | 32.44M | 34.57M |
| Research & development | 4.40M | 7.98M | 13.67M | 4.56M | 5.24M | 5.19M |
| Operating profit | 41.43M | 48.75M | 34.58M | 38.99M | 38.15M | 50.86M |
| Pretax profit | -38.59M | 72.60M | 97.82M | 195.04M | 234.56M | -108.02M |
| Tax | 8.00M | 8.91M | 7.91M | 30.88M | 47.97M | -24.60M |
| Net profit | -46.58M | 63.69M | 89.91M | 164.15M | 186.60M | -83.42M |
| Basic EPS | -1 | 1 | 1 | 2 | 3 | -1 |
| Diluted EPS | -0.74 | 0.77 | 1.08 | 1.94 | 2.22 | -1.14 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 199.04M | 431.23M | 342.06M | 313.67M | 443.51M | 344.22M | 554.31M | 727.52M |
| Cash & ST investments | 114.91M | 350.85M | 246.49M | 201.53M | 291.05M | 193.51M | 412.50M | 566.67M |
| Inventory | -- | -- | -- | 0 | 55.90M | 40.74M | 33.73M | 39.17M |
| Total assets | 548.19M | 724.83M | 999.57M | 926.40M | 1.23B | 1.24B | 1.30B | 1.64B |
| Total current liabilities | 5.70M | 5.37M | 6.11M | 5.81M | 134.97M | 38.13M | 236.08M | 49.70M |
| Short-term debt | -- | -- | -- | 106.00K | 97.51M | 1.21M | 193.60M | 418.00K |
| Long-term debt | 382.86M | 377.12M | 385.52M | 394.65M | 444.18M | 446.23M | 256.32M | 257.73M |
| Total liabilities | 389,141,000.00 | 382,710,000.00 | 391,733,000.00 | 400,460,000.00 | 665,709,000.00 | 568,552,000.00 | 609,901,000.00 | 462,324,000.00 |
| Total equity | 159.05M | 342.12M | 607.84M | 525.94M | 565.79M | 674.96M | 691.16M | 1.17B |
| Retained earnings | -1.10B | -946.40M | -722.00M | -456.15M | -204.91M | -25.19M | -1.80M | 269.37M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 582.02M | 651.78M | 684.57M | 727.52M | 772.62M | 753.37M |
| Cash & ST investments | 446.88M | 497.73M | 533.10M | 566.67M | 611.93M | 579.06M |
| Inventory | 41.48M | 49.00M | 38.36M | 39.17M | 38.84M | 38.97M |
| Total assets | 1.25B | 1.33B | 1.43B | 1.64B | 1.84B | 1.70B |
| Total current liabilities | 234.75M | 246.56M | 48.47M | 49.70M | 36.56M | 47.06M |
| Short-term debt | 193.50M | 192.89M | 680.00K | 418.00K | 646.00K | 712.00K |
| Long-term debt | 256.67M | 257.02M | 257.38M | 257.73M | 258.10M | 258.45M |
| Total liabilities | 607,485,000.00 | 618,751,000.00 | 419,155,000.00 | 462,324,000.00 | 494,932,000.00 | 469,465,000.00 |
| Total equity | 646.91M | 714.82M | 1.01B | 1.17B | 1.34B | 1.23B |
| Retained earnings | -48.38M | 15.31M | 105.22M | 269.37M | 455.96M | 372.54M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 223.53M | 257.46M | 313.11M | 363.81M | 201.73M | 141.06M | 188.69M | 196.93M |
| Depreciation & amortization | 13.87M | 13.87M | 0 | 0 | 5.58M | 21.78M | 25.90M | 26.28M |
| Free cash flow | 223.53M | 257.45M | 313.10M | 363.81M | 201.66M | 140.65M | 184.42M | 186.43M |
| Dividends paid | -80.00K | -11.00K | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.93M | 538.00K | 344.00K | -393.04M | -8.22M | -75.64M | -13.45M | -2.12M |
| Ending cash balance | 62.42M | 278.10M | 246.49M | 201.53M | 291.05M | 193.51M | 304.96M | 550.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 48.62M | 44.07M | 49.73M | 54.51M | 35.28M | 51.97M |
| Depreciation & amortization | 6.48M | 6.55M | 6.62M | 6.64M | 6.55M | 6.63M |
| Free cash flow | 48.62M | 44.07M | 39.24M | 54.50M | 34.79M | 51.54M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 183.00K | 1.25M | 169.00K | -3.72M | -20.15M | -29.41M |
| Ending cash balance | 319.09M | 397.53M | 476.51M | 550.94M | 603.09M | 570.39M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | 67.35 | 52.59 | 55.70 | 43.63 | 28.97 | 3.42 | 29.10 |
| ROA %i | 86.30 | 24.71 | 26.03 | 27.61 | 19.83 | 14.52 | 1.84 | 18.47 |
| ROIC %i | -- | 27.39 | 29.50 | 32.29 | 21.93 | 16.37 | 2.23 | 20.71 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 49.65 | 36.86 | 32.16 |
| EBIT margin %i | 89.73 | 96.38 | 110.62 | 118.50 | 91.37 | 68.69 | 16.61 | 83.52 |
| FCF / sales %i | 85.64 | 98.63 | 92.96 | 92.84 | 60.86 | 45.30 | 51.41 | 45.32 |
| Current ratioi | 34.92 | 80.29 | 55.98 | 54.02 | 3.29 | 9.03 | 2.35 | 14.64 |
| Quick ratioi | 34.77 | 80.11 | 55.71 | 53.77 | 2.63 | 7.28 | 2.11 | 13.28 |
| Debt / assetsi | 69.84 | 52.03 | 38.57 | 42.61 | 44.18 | 36.11 | 34.67 | 16.45 |
| LT debt / equityi | 249.28 | 120.30 | 71.40 | 95.16 | 78.93 | 66.36 | 37.26 | 22.90 |
| Interest coveragei | 9.78 | 13.48 | 20.32 | 24.35 | 19.17 | 11.13 | 2.68 | 20.57 |
| Revenue CAGR (3Y) %i | 69.13 | 25.02 | 15.74 | 14.51 | 8.28 | -2.68 | -2.90 | 7.47 |
| Net income CAGR (3Y) %i | -- | 38.24 | 18.71 | -12.37 | 10.79 | -7.13 | -55.52 | 8.22 |
| FCF CAGR (3Y) %i | 180.54 | 61.86 | 30.23 | 17.63 | -7.82 | -23.41 | -20.27 | -2.58 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -8.84 | 5.60 | 15.17 | 29.10 | 50.72 | 36.68 |
| ROA %i | -4.74 | 3.02 | 9.57 | 18.47 | 32.63 | 23.53 |
| ROIC %i | -5.18 | 3.33 | 10.49 | 20.71 | 36.60 | 26.01 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -6.83 | 23.09 | 44.95 | 83.52 | 146.77 | 99.46 |
| FCF / sales %i | 52.99 | 53.03 | 48.17 | 45.32 | 41.03 | 40.93 |
| Current ratioi | 2.48 | 2.64 | 14.12 | 14.64 | 21.13 | 16.01 |
| Quick ratioi | 2.24 | 2.38 | 12.93 | 13.28 | 19.27 | 14.65 |
| Debt / assetsi | 35.97 | 33.81 | 18.12 | 16.45 | 14.67 | 15.84 |
| LT debt / equityi | 39.85 | 36.10 | 25.57 | 22.90 | 20.03 | 21.81 |
| Interest coveragei | -1.20 | 4.29 | 9.63 | 20.57 | 35.44 | 24.00 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Royalty revenue is the largest reported line at 47.11% of revenue, across 6 reported segments.
- XACDURO® follows at 18.72%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Royalty revenue47.11%
XACDURO®18.72%
GIAPREZA®18.65%
License and other revenue9.60%
XERAVA®5.64%
ZEVTERA®0.29%
Quote time 2026-10-08 07:40:13 · For reference only, not investment advice and not tailored to your situation.